A clinical trial conducted by Canadian Centre for Agri-food Research In Health and Medicine principal investigator and medical microbiologist Dr. Michelle Alfa was celebrated today for its contribution to the development of a commercial product. MSPrebiotic® is used for improving gut health in both mid-age and elderly adults, and is manufactured in Manitoba by MSPrebiotics Inc., Carberry MB, host of the event.
Participants in the clinical trial were invited to a presentation of the results by Dr. Alfa, and enjoyed a reception following the presentation.
In conjunction with Dr. David Strang, chief medical officer at Deer Lodge Centre, Dr. Alfa undertook a Health Canada cleared prospective, randomized clinical trial that evaluated the prebiotic in mid-age adults (30 to 50 years of age) as well as elderly (70 years and older) adults. The objective of the clinical trial was to determine if the consumption of MSPrebiotic® could alter the microbiome or decrease glucose and insulin resistance (thereby reducing the risk of Type 2 Diabetes). The study found that there was also a significant reduction in the glucose in older adults as well as a significant reduction in Insulin resistance, findings which indicate that MSPrebiotic® could be a valuable way to reduce the risk of Type 2 Diabetes.